HRP20121005T1 - Dozirani oblik koji sadrži pantoprazol kao aktivni sastojak - Google Patents
Dozirani oblik koji sadrži pantoprazol kao aktivni sastojak Download PDFInfo
- Publication number
- HRP20121005T1 HRP20121005T1 HRP20121005TT HRP20121005T HRP20121005T1 HR P20121005 T1 HRP20121005 T1 HR P20121005T1 HR P20121005T T HRP20121005T T HR P20121005TT HR P20121005 T HRP20121005 T HR P20121005T HR P20121005 T1 HRP20121005 T1 HR P20121005T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- core
- form according
- pantoprazole
- granules
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims 15
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 title claims 3
- 229960005019 pantoprazole Drugs 0.000 title claims 3
- 239000004480 active ingredient Substances 0.000 title 1
- 239000008187 granular material Substances 0.000 claims 11
- RDRUTBCDIVCMMX-UHFFFAOYSA-N magnesium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC.COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC RDRUTBCDIVCMMX-UHFFFAOYSA-N 0.000 claims 8
- 239000010410 layer Substances 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 208000000718 duodenal ulcer Diseases 0.000 claims 3
- 239000002702 enteric coating Substances 0.000 claims 3
- 238000009505 enteric coating Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 210000004051 gastric juice Anatomy 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 150000002484 inorganic compounds Chemical class 0.000 claims 2
- 229910010272 inorganic material Inorganic materials 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 235000017550 sodium carbonate Nutrition 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000012055 enteric layer Substances 0.000 claims 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000011229 interlayer Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Čvrsti dozirni oblik kao tableta ili zrnce, naznačen time, da je otporan na želučani sok za oralnu primjenu pantoprazol magnezij dihidrata, gdje svaka tableta ili zrnce sadrži jezgru u kojoj je terapeutski učinkovita količina pantoprazol magnezij dihidrata u smjesi s vezivom, punilom i opcijski, sa sastojkom odabranim iz skupine koju čine pomoćno sredstvo neke druge tablete i bazični fiziološki prihvatljiv anorganski spoj, inertni međusloj topiv u vodi koji opkoljava jezgru i vanjski sloj, koji je otporan na želučani sok, u čemu je vezivo polivinilpirolidon lagane molekularne težine s prosječnom molekularnom težinom ispod 300 000 i/ili hidroksipropilmetil celuloza, te opcijski, punilo ja manitol.
2. Dozirni oblik prema zahtjevu 1, naznačen time, da je to dozirni oblik s odgođenim otpuštanjem koji sadrži enterički sloj topiv u neutralnim ili alkalijskim uvjetima i barem jedan međusloj (podobložni sloj).
3. Dozirni oblik prema zahtjevu 1, naznačen time, da bazični, fiziološki prihvatljiv anorganski spoj je farmakološki prihvatljiv alkalijski metal, zemno-alkalijski metal ili zemna metalna sol od slabe kiseline ili farmakološki prihvatljiv hidroksid ili oksid zemno-alkalijskog ili zemnog metala.
4. Dozirni oblik prema bilo kojem od zahtjeva 1 do 3, naznačen time, da on sadrži pantoprazol magnezij dihidrat zajedno s polivinilpirolidonom lagane molekularne težine u alkalijskoj jezgri zrnca ili tablete.
5. Dozirni oblik prema bilo kojem od zahtjeva 1 do 4, naznačen time, da on sadrži sljedeća pomoćna sredstva za tabletnu jezgru: natrijev karbonat, manitol, krospovidon, polivinilpirolidon lagane molekularne težine, te magnezijev ili kalcijev stearat.
6. Dozirni oblik prema bilo kojem od zahtjeva 1 do 5, u obliku zrnca, naznačen time, da on sadrži jezgru zrnca, međusloj i enteričku oblogu, gdje je jezgra zrnca oblikovana od početnih zrnaca, pantoprazol magnezij dihidrata, škroba i opcijski od ostalih pomoćnih sredstava.
7. Dozirni oblik prema zahtjevu 6, u obliku zrnca, naznačen time, da on sadrži jezgru zrnca, međusloj i enteričku oblogu, gdje je jezgra zrnca oblikovana od početnih zrnaca sukroze, pantoprazol magnezij dihidrata, natrijevog karbonata, PVP 25, želatiniziranog škroba i natrijevog dodecilsulfata, dok je međusloj oblikovan od HPMC, PVP 25, titan dioksida i žutog željeznog oksida, a enterička obloga je sačinjena od Eudragit L 30 D i trietil citrata.
8. Dozirni oblik prema bilo kojem od zahtjeva 1 do 7, naznačen time, da sadrži između 5 i 100 mg pantoprazol magnezij dihidrata.
9. Dozirni oblik prema zahtjevu 8, naznačen time, da sadrži količinu pantoprazol magnezij dihidrata, koja predstavlja 10, 20, 40, 50, 80 ili 100 mg pantoprazola (slobodna kiselina).
10. Dozirni oblik prema zahtjevu 9, naznačen time, da sadrži količinu pantoprazol magnezij dihidrata, koja predstavlja 40 ili 80 mg pantoprazola (slobodna kiselina).
11. Dozirni oblik prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se upotrebljava za profilaksu ili liječenje kliničkog stanja kod sisavaca, gdje je kliničko stanje odabrano iz skupine koju čine: benigni gastrični ulkus, bolest gastro-ezofagealnog refluksa, Zollinger-Ellison-sindrom, duodenalni ulkus, duodenalni ulkus povezan s bakterijom Helicobacter pylori, profilaksa za gastrični ili duodenalni ulkus povezan s NSAID kod pacijenata s povećanim rizikom za gastroduodenalne komplikacije, koje zahtijevaju sustavno NSAID liječenje i kombinacijsku terapiju s antibioticima za eradikaciju bakterije Helicobacter pylori.
12. Dozirni oblik za uporabu prema zahtjevu 11, naznačen time, da sisavac je čovjek.
13. Dozirni oblik za uporabu prema zahtjevu 11 ili 12, naznačen time, da kliničko stanje je gastro-ezofagealna refluksna bolest (GERD).
14. Dozirni oblik za uporabu prema zahtjevu 13, naznačen time, da kliničko stanje je GERD I do III (prema Savary/Miller klasifikaciji).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03010328 | 2003-05-08 | ||
EP04001754 | 2004-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20121005T1 true HRP20121005T1 (hr) | 2013-01-31 |
Family
ID=33436112
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120754TT HRP20120754T1 (hr) | 2003-05-08 | 2012-09-24 | Dozirni oblik koji sadrži pantoprazol kao aktivni sastojak |
HRP20121005TT HRP20121005T1 (hr) | 2003-05-08 | 2012-12-06 | Dozirani oblik koji sadrži pantoprazol kao aktivni sastojak |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120754TT HRP20120754T1 (hr) | 2003-05-08 | 2012-09-24 | Dozirni oblik koji sadrži pantoprazol kao aktivni sastojak |
Country Status (27)
Country | Link |
---|---|
US (2) | US20060240100A1 (hr) |
EP (2) | EP1624869B1 (hr) |
JP (2) | JP4878284B2 (hr) |
KR (2) | KR20110104124A (hr) |
AR (1) | AR044264A1 (hr) |
AU (2) | AU2004237363B2 (hr) |
BR (2) | BRPI0410044B8 (hr) |
CA (1) | CA2489140C (hr) |
CL (1) | CL2004000983A1 (hr) |
CY (2) | CY1113128T1 (hr) |
DK (2) | DK2316454T3 (hr) |
EA (2) | EA027734B1 (hr) |
ES (2) | ES2396197T3 (hr) |
HK (1) | HK1090546A1 (hr) |
HR (2) | HRP20120754T1 (hr) |
IL (2) | IL171365A (hr) |
MX (1) | MXPA05000411A (hr) |
NO (1) | NO337921B1 (hr) |
NZ (1) | NZ543181A (hr) |
PE (1) | PE20050199A1 (hr) |
PL (2) | PL1624869T3 (hr) |
PT (2) | PT2316454E (hr) |
RS (1) | RS53443B (hr) |
SI (2) | SI1624869T1 (hr) |
TW (1) | TW200509992A (hr) |
WO (1) | WO2004098594A2 (hr) |
ZA (1) | ZA200508202B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
CA2565083C (en) | 2004-05-07 | 2014-07-08 | Altana Pharma Ag | Novel pharmaceutical dosage form and manufacturing process |
AR054358A1 (es) * | 2005-05-13 | 2007-06-20 | Combino Pharm Sl | Formulaciones que contienen pantoprazol libre de acido y sus sales |
EP1747776A1 (en) * | 2005-07-29 | 2007-01-31 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising granular pantoprazole |
TWI519322B (zh) * | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | 包含弱鹼性藥物及控制釋放劑型之組合物 |
WO2010018593A2 (en) * | 2008-07-03 | 2010-02-18 | Torrent Pharmaceuticals Ltd. | Gastric acid resistant benzimidazole multiple unit tablet composition |
WO2012010944A2 (en) * | 2010-07-22 | 2012-01-26 | Lupin Limited | Multiple unit tablet composition |
KR101787481B1 (ko) | 2010-10-21 | 2017-10-18 | 롯데정밀화학 주식회사 | 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐 |
ITMI20111168A1 (it) * | 2011-06-27 | 2012-12-28 | Professional Dietetics Srl | Composizioni farmaceutiche comprendenti idrossipropilmetilcellulosa e/o acido ialuronico e loro uso |
WO2014016754A2 (en) * | 2012-07-26 | 2014-01-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
WO2018065952A1 (en) * | 2016-10-06 | 2018-04-12 | Jubilant Generics Limited | Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof |
WO2023214016A1 (en) * | 2022-05-06 | 2023-11-09 | Evonik Operations Gmbh | Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
IL85472A (en) | 1987-03-09 | 1991-06-30 | Procter & Gamble | Pharmaceutical compositions for treating gastrointestinal disorders |
JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
DE3901151A1 (de) | 1989-01-17 | 1990-07-19 | Hoechst Ag | Stabile pharmazeutische zubereitungen von thienoimidazol-derivaten und deren orale anwendung als magensaeuresekretionshemmer |
DK0474098T3 (da) * | 1990-08-30 | 1994-05-02 | Senju Pharma Co | Middel til kontrolleret lægemiddelfrigivelse |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
EP0617612B1 (en) * | 1991-12-18 | 1997-09-10 | Warner-Lambert Company | A process for the preparation of a solid dispersion |
JPH08509736A (ja) * | 1993-04-27 | 1996-10-15 | セプラコー,インコーポレイテッド | 光学的に純粋な(−)パントプラゾールを用いる胃の疾患治療の方法と組成 |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
KR100384960B1 (ko) | 1994-07-08 | 2003-08-21 | 아스트라제네카 악티에볼라그 | 다단위정제투여형i |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE508669C2 (sv) | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
JP3249914B2 (ja) * | 1996-06-04 | 2002-01-28 | 清水食品株式会社 | 成型用焼結金型およびその形成方法 |
EP0866084A3 (en) * | 1997-03-21 | 2002-02-27 | Mitsui Chemicals, Inc. | Production process of cross-linked polyaspartic acid resin |
WO1999027917A1 (de) * | 1997-11-28 | 1999-06-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe |
CA2310585C (en) | 1997-12-08 | 2005-08-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel administration form comprising an acid-labile active compound |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
HU228772B1 (en) * | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same |
ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
JP3274416B2 (ja) * | 1998-05-29 | 2002-04-15 | 佐藤製薬株式会社 | 口腔内崩壊性粒状製剤 |
ATE321538T1 (de) | 1998-08-12 | 2006-04-15 | Altana Pharma Ag | Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole |
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
MXPA01012659A (es) | 1999-06-07 | 2003-09-04 | Altana Pharma Ag | Nueva forma de administracion y preparacion que comprende un compuesto activo labil acido. |
US6420473B1 (en) * | 2000-02-10 | 2002-07-16 | Bpsi Holdings, Inc. | Acrylic enteric coating compositions |
US6346269B1 (en) * | 2000-05-08 | 2002-02-12 | Standard Chem. & Pharm. Co., Ltd. | Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby |
SI20720A (sl) * | 2000-11-20 | 2002-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola |
MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
AU2002221939A1 (en) | 2000-12-07 | 2002-06-18 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Rapidly disintegrating tablet comprising an acid-labile active ingredient |
ES2403238T3 (es) * | 2000-12-07 | 2013-05-16 | Takeda Gmbh | Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
CA2565083C (en) | 2004-05-07 | 2014-07-08 | Altana Pharma Ag | Novel pharmaceutical dosage form and manufacturing process |
JP4563077B2 (ja) * | 2004-05-28 | 2010-10-13 | 株式会社ロッテ | キャンディ及びその製造方法 |
-
2004
- 2004-05-04 CL CL200400983A patent/CL2004000983A1/es unknown
- 2004-05-05 PE PE2004000457A patent/PE20050199A1/es not_active Application Discontinuation
- 2004-05-07 TW TW093113016A patent/TW200509992A/zh unknown
- 2004-05-07 PL PL04741525T patent/PL1624869T3/pl unknown
- 2004-05-07 JP JP2006505591A patent/JP4878284B2/ja not_active Expired - Fee Related
- 2004-05-07 BR BRPI0410044A patent/BRPI0410044B8/pt active IP Right Grant
- 2004-05-07 PL PL10175417T patent/PL2316454T3/pl unknown
- 2004-05-07 SI SI200431922T patent/SI1624869T1/sl unknown
- 2004-05-07 BR BR122016006880A patent/BR122016006880B8/pt active IP Right Grant
- 2004-05-07 KR KR1020117019680A patent/KR20110104124A/ko not_active Application Discontinuation
- 2004-05-07 EP EP04741525A patent/EP1624869B1/en not_active Expired - Lifetime
- 2004-05-07 DK DK10175417.4T patent/DK2316454T3/da active
- 2004-05-07 CA CA002489140A patent/CA2489140C/en not_active Expired - Lifetime
- 2004-05-07 RS YU20050818A patent/RS53443B/en unknown
- 2004-05-07 WO PCT/EP2004/050729 patent/WO2004098594A2/en active Application Filing
- 2004-05-07 EA EA201101119A patent/EA027734B1/ru not_active IP Right Cessation
- 2004-05-07 AU AU2004237363A patent/AU2004237363B2/en not_active Ceased
- 2004-05-07 US US10/555,238 patent/US20060240100A1/en not_active Abandoned
- 2004-05-07 EA EA200501697A patent/EA016824B1/ru not_active IP Right Cessation
- 2004-05-07 DK DK04741525.2T patent/DK1624869T3/da active
- 2004-05-07 ES ES10175417T patent/ES2396197T3/es not_active Expired - Lifetime
- 2004-05-07 SI SI200431976T patent/SI2316454T1/sl unknown
- 2004-05-07 KR KR1020057020740A patent/KR101237742B1/ko active IP Right Grant
- 2004-05-07 ES ES04741525T patent/ES2390342T3/es not_active Expired - Lifetime
- 2004-05-07 PT PT101754174T patent/PT2316454E/pt unknown
- 2004-05-07 PT PT04741525T patent/PT1624869E/pt unknown
- 2004-05-07 EP EP10175417A patent/EP2316454B9/en not_active Expired - Lifetime
- 2004-05-07 MX MXPA05000411A patent/MXPA05000411A/es active IP Right Grant
- 2004-05-07 NZ NZ543181A patent/NZ543181A/en unknown
- 2004-05-07 AR ARP040101558A patent/AR044264A1/es not_active Application Discontinuation
-
2005
- 2005-10-11 IL IL171365A patent/IL171365A/en active IP Right Grant
- 2005-10-11 ZA ZA2005/08202A patent/ZA200508202B/en unknown
- 2005-11-29 NO NO20055631A patent/NO337921B1/no not_active IP Right Cessation
-
2006
- 2006-10-11 HK HK06111165.0A patent/HK1090546A1/xx not_active IP Right Cessation
-
2009
- 2009-04-03 US US12/385,280 patent/US8703192B2/en not_active Expired - Fee Related
-
2010
- 2010-03-10 AU AU2010200905A patent/AU2010200905B2/en not_active Ceased
-
2011
- 2011-03-16 JP JP2011057961A patent/JP5162689B2/ja not_active Expired - Fee Related
-
2012
- 2012-09-19 CY CY20121100860T patent/CY1113128T1/el unknown
- 2012-09-24 HR HRP20120754TT patent/HRP20120754T1/hr unknown
- 2012-12-06 HR HRP20121005TT patent/HRP20121005T1/hr unknown
- 2012-12-12 CY CY20121101214T patent/CY1113462T1/el unknown
-
2013
- 2013-11-20 IL IL229510A patent/IL229510A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20121005T1 (hr) | Dozirani oblik koji sadrži pantoprazol kao aktivni sastojak | |
US7803817B2 (en) | Composition and methods for inhibiting gastric acid secretion | |
US6544556B1 (en) | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor | |
CN101002939A (zh) | 一类治疗与胃酸有关疾病的药物组合制剂 | |
US9370481B2 (en) | Compositions and methods for inhibiting gastric acid secretion | |
CA2524979A1 (en) | Solid dosage form comprising (s)-pantoprazole magnesium salt | |
US9233092B2 (en) | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI | |
WO2013122554A1 (en) | Pellet formulations comprising esomeprazole | |
CA2563162A1 (en) | Dosage form containing pantoprazole as active ingredient | |
JP2023114904A (ja) | エソメプラゾール含有顆粒及びそれを含む口腔内崩壊錠 | |
KR20240014209A (ko) | 덱스란소프라졸 함유 정제 | |
JP2023114903A (ja) | エソメプラゾール含有口腔内崩壊錠の製造方法 |